November 2024 in “Skin Appendage Disorders” Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.
October 2014 in “Journal of Minimally Invasive Gynecology” Genetic testing for cancer risk can lead to early and life-saving treatments in people without symptoms.
February 2026 in “Clinical Drug Investigation” Baricitinib significantly improves nail and hair symptoms in severe alopecia areata.
1 citations
,
January 2000 in “PubMed” The treatment slightly increased hair growth and was safe for most women.
January 2005 in “Translational and Clinical Pharmacology” HDMHG0401-10 improves hair loss in men with androgenetic alopecia and has no major side effects.
3 citations
,
March 2018 in “European Urology Supplements” Using 5-alpha-reductase inhibitors may improve bladder cancer survival in men.
August 2025 in “Pediatric Dermatology” The program improved students' understanding and acceptance of alopecia areata.
June 2025 in “British Journal of Dermatology” Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.
1 citations
,
July 2026 in “Dermatology and Therapy” JAK inhibitors are generally safe for alopecia areata and atopic dermatitis, with mostly mild side effects.
December 2025 in “Clinical & Experimental Dermatology and Therapies” Cosmerna ARI effectively reduces hair loss and increases hair density in Europeans with androgenetic alopecia.
January 2024 in “Skin Research and Technology” Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.
February 2026 in “Molecules” BBR-SA nanomedicine is a safe and effective treatment for breast cancer.
August 2023 in “JAAD international” Pediatric dermatologists have varied preferences for treating alopecia areata in children, with no standard FDA-approved treatments and some using JAK inhibitors despite risks.
May 2026 in “Open Science Framework” Biochanin A from soy is a promising and safe candidate for treating hair loss.
20 citations
,
January 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is the most effective treatment for alopecia areata.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata.
February 2026 in “Cureus” Crisaborole may help regrow hair in children with alopecia areata.
28 citations
,
July 2015 in “Dermatologic therapy” The combined therapy was effective and safe for children with severe alopecia areata.
7 citations
,
January 2021 in “The Journal of Sexual Medicine” Testosterone with dutasteride improves muscle strength and body composition in trans men.
3 citations
,
July 2024 in “Journal of the American Academy of Dermatology” Dermatologists are hesitant to prescribe Janus kinase inhibitors for alopecia areata due to safety concerns and lack of knowledge.
September 2017 in “Journal of Investigative Dermatology” Injections of special skin cells showed potential in treating hair loss, with some participants experiencing increased hair density.
3 citations
,
September 2022 in “Archives of dermatological research” The fractional carbon dioxide laser is a safe and effective treatment for alopecia areata and works better than betamethasone valerate cream alone.
24 citations
,
December 2010 in “Dermatologic surgery” Botulinum toxin type A injections are not effective for severe alopecia areata.
18 citations
,
August 2012 in “Chinese journal of integrative medicine/Chinese Journal of Integrative Medicine” Both treatments for alopecia areata are equally effective and safe.
July 2025 in “The Journal of Dermatology” Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.
69 citations
,
August 2008 in “Journal of The European Academy of Dermatology and Venereology” Oral dutasteride and topical pimecrolimus can safely and effectively treat Frontal Fibrosing Alopecia, leading to significant hair regrowth.
11 citations
,
November 2018 in “British Journal of Dermatology” Oxymetazoline cream 1.0% effectively reduces rosacea redness, and using baseline photos improves assessment accuracy.
June 2022 in “Value in Health” Adding Baricitinib for severe alopecia areata will have a small impact on a health plan's budget.
March 2014 in “Journal of The American Academy of Dermatology” The new topical product combined with finasteride significantly increased hair thickness without side effects.